Helex Bio
Revolutionizing genomic medicines for kidney diseases
- Employees
- 1–10
- Business Model
- B2B
- Website
- helex.bio
- Total Funding
- $3.5M
- Last Round
- $3.5M SeedOct 2025
- Rounds
- 1
About
Helex is a US and India-based early-stage biotechnology company developing non-viral gene editing therapeutics for genetic kidney diseases. Its proprietary Epic-Cure™ technology enables precision de-risked drug design, and its lipid nanoparticle platform enables targeted kidney delivery. The company's lead program targets Autosomal Dominant Polycystic Kidney Disease (ADPKD), with ambitions to build a broad renal gene therapy franchise.
Summary
Helex Bio is a Biotech company. It has raised $3.5M in total across 1 round, most recently a $3.5M Seed round in Oct 2025. Investors include pi Ventures and SOSV.
Tech & App Stack
5 technologies & apps tracked
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Oct 2025
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.